KISIMA™ cancer vaccine (ATP-128): a self-adjuvanting, multi-antigenic, peptide-based cancer vaccine
Our KISIMA™ cancer vaccine (ATP-128)* is a modular self-adjuvanting peptide-based cancer vaccine that carries a multi-antigenic cargo, which has the potential to strengthen the capability of the patient’s immune system to recognise and kill tumour cells.1
Clinical trials (monotherapy and combination therapy): Our KISIMA™ cancer vaccine (ATP-128) is being investigated as a monotherapy and in combination with the investigational programmed death-1 (PD-1) inhibitor BI 754091* in patients with advanced colorectal cancer (CRC).2
About KISIMA™ cancer vaccine (ATP-128)
The ATP-128 vaccine is based on the KISIMA® technology platform
Our ATP-128 cancer vaccine ATP-128 is a therapeutic chimaeric recombinant protein vaccine based on the KISIMA® technology platform.1 The KISIMA® platform is engineered to induce an efficient immune response via activation of helper and cytotoxic T cells, and to promote immunological memory.3
In order to induce a potent tumour-specific immune response, a therapeutic vaccine needs to stimulate multi-epitopic CD8+ cytotoxic T lymphocyte-mediated immunity, induce CD4+ helper T cells and promote immunological memory.4 Our KISIMA™ cancer vaccine (ATP-128) therefore includes three components in a single fusion protein, which is then used as a vaccine: first, a cell-penetrating peptide for antigen delivery; second, a multi-antigenic cargo that is tailored to raise an immune response against colorectal tumours; and third, a toll-like receptor (TLR) peptide agonist as an adjuvant.3
Functional components of our KISIMA™ cancer vaccine (ATP-128)3
Our ATP-128 cancer vaccine is based on the KISIMA® technology platform, and includes three components designed to penetrate cells, raise a tumour-specific immune response and provide co-stimulatory signals.3
Adapted from Belnoue E, et al. JCI Insight 2019;4(11):e127305.
TLR, toll-like receptor.
Mechanism of action
Our KISIMA™ cancer vaccine (ATP-128) is designed to induce a tumour-specific adaptive immune response via the following hypothesised steps:1,3-5
Peptide-based immunotherapeutic cancer vaccine mechanism of action1,3-5
CD, cluster of differentiation; CRC, colorectal cancer; CTL, cytotoxic T lymphocyte; MHC, major histocompatibility complex.
Preclinical evidence supports the safety and immunogenicity of a previous generation of the KISIMA™ cancer vaccine (ATP-128) in an in vivo model of CRC.3 This cancer vaccine has been shown to induce highly potent helper and cytotoxic T-cell responses in several murine tumour models.3 The cell-penetrating peptide and the TLR agonist components of the vaccine platform have been shown to act together to elicit both CD8+ and CD4+ antigen-specific T-cell immune responses in vivo.3
The vaccine also resulted in favourable changes in the tumour microenvironment, including tumour infiltration of antigen-specific effector T cells, reduction of myeloid-derived suppressor cells and regulatory T cells, and M1 polarisation of macrophages.3
Combination with PD-1 blockade has been shown to have an additive effect and to significantly increase the efficacy of the KISIMA™ cancer vaccine (ATP-128) in vivo.5 T-cell infiltration, this could sensitise PD-1-resistant tumours (which have been shown to have limited immune infiltration) to checkpoint inhibitors.3
Our KISIMA™ cancer vaccine (ATP-128) is currently being investigated as a monotherapy and in combination with the PD-1 inhibitor BI 754091 in patients with Stage IV CRC.2
AE, adverse event; BOR, best overall response; DoR, duration of response; ORR, objective response rate; PD-1, programmed cell death protein 1; PFS, progression-free survival; RFS, relapse-free survival; RP2D, recommended Phase II dose.
Boehringer Ingelheim. Press release. https://www.boehringer-ingelheim.com/press-release/acquisition-amal-therapeutics (Accessed: March 2020).
ClinicalTrials.gov. NCT04046445. https://clinicaltrials.gov/ct2/show/NCT04046445 (Accessed: March 2020).
Belnoue E, et al. JCI Insight 2019;4(11):e127305.
AMAL Therapeutics. Therapeutic Vaccines. http://amaltherapeutics.com/science/therapeutic-vaccines/ (Accessed: March 2020).
Boehringer Ingelheim. Data on file.
*This is an investigational compound and has not been approved. Its safety and efficacy have not been established.
© 2020 Boehringer Ingelheim International GmbH. All rights reserved.
Page last updated: March 2020
Some links in this area will let you leave Boehringer Ingelheim's site and visit external websites. If not indicated otherwise in the imprint of the external website, the linked sites are not under the control of the Boehringer Ingelheim corporation and no entity of the Boehringer Ingelheim group of companies is responsible for the contents of such linked site or any link contained in such linked site, or any changes or updates to such sites. Neither is any entity of the Boehringer Ingelheim group of companies responsible for webcasting or any other form of transmission received from any linked site. These links are provided to you only as a convenience, and the inclusion of any link does not imply endorsement by the Boehringer Ingelheim group of companies of the site. In particular, Boehringer Ingelheim is not in a position to monitor the linked third party websites completely and permanently for violations of the law. Boehringer Ingelheim therefore accepts no responsibility for the accuracy or any other aspect of the information on this website. Boehringer Ingelheim is liable, if at all, only to the extent that it was aware of illegal content and it was technically possible and reasonable to prevent its use. The data protection declaration for this website does not apply to such linked websites.
Do you want to continue ?Continue